Phospho-Ser784-VCP is required for DNA damage response and is associated with poor prognosis of chemotherapy-treated breast cancer

Authors

Cuige Zhu, Washington University School of Medicine in St. Louis
Anna Rogers, Washington University School of Medicine in St. Louis
Karama Asleh, University of British Columbia
Jennifer Won, University of British Columbia
Dongxia Gao, University of British Columbia
Samuel Leung, University of British Columbia
Shan Li, Washington University School of Medicine in St. Louis
Kiran R Vij, Washington University School of Medicine in St. Louis
Jian Zhu, Washington University School of Medicine in St. Louis
Jason M Held, Washington University School of Medicine in St. Louis
Zhongsheng You, Washington University School of Medicine in St. Louis
Torsten O Nielsen, University of British Columbia
Jieya Shao, Washington University School of Medicine in St. Louis

Journal

Cell Reports

Publication Date

6-9-2020

Volume

31

Issue

10

First Page

107745

Document Type

Open Access Publication

DOI

10.1016/j.celrep.2020.107745

Rights and Permissions

Zhu C, Rogers A, Asleh K, et al. Phospho-Ser784-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. Cell Rep. 2020;31(10):107745. doi:10.1016/j.celrep.2020.107745 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Zhu, Cuige; Rogers, Anna; Asleh, Karama; Won, Jennifer; Gao, Dongxia; Leung, Samuel; Li, Shan; Vij, Kiran R; Zhu, Jian; Held, Jason M; You, Zhongsheng; Nielsen, Torsten O; and Shao, Jieya, "Phospho-Ser784-VCP is required for DNA damage response and is associated with poor prognosis of chemotherapy-treated breast cancer." Cell Reports. 31, 10. 107745 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9151